Fecal Bacteriotherapy (FBT), also referred to as Fecal Transplant, is a treatment method used to cure patients of recurrent Clostridium difficile Infection (CDI). Patients with CDI treated with antimicrobial therapy can experience relapse rates of up to 20% and 70% after first and second CDI episodes respectively. Michael Garron Hospital (MGH) began formally treating patients suffering from CDI with FBT in 2015 to provide a more effective treatment option for patients with recurrent infection. FBT is a procedure in which healthy stool received from a screened donor is prepared and inserted into the patient through either a nasogastric or rectal route. An evaluation of procedures completed in 2018 shows that FBT has achieved long-term cure rates of up to 96% measured at 1-month following the procedure.

The success of FBT helps to restore patients’ quality of life as patients suffering from recurrent CDI endure abdominal pain and intractable diarrhea that in severe cases could lead to the need for surgery or even death. MGH invites patients to tell their story of how FBT has enabled them to return to their regular daily activities. Engaging patients to share their stories with the broader community has helped MGH establish three universal donors which are essential to the sustainability of FBT.

MGH shares its expertise and experiences of its FBT program and invites hospital centres around Ontario to adopt this treatment so that patients with CDI can access successful treatment locally within their own community. 

← Back to Search Results

Leading Practices are submitted by health organizations from around the world. The contents of the Leading Practices library do not reflect opinions or views of HSO or its affiliates. If you have questions, concerns or suggestions please email us at leadingpractices@healthstandards.org